1. Home
  2. KNSA vs OWL Comparison

KNSA vs OWL Comparison

Compare KNSA & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

N/A

Current Price

$95.50

Market Cap

7.7B

Sector

Health Care

ML Signal

N/A

Logo Blue Owl Capital Inc.

OWL

Blue Owl Capital Inc.

N/A

Current Price

$9.22

Market Cap

6.9B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
KNSA
OWL
Founded
2015
2020
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
6.9B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KNSA
OWL
Price
$95.50
$9.22
Analyst Decision
Strong Buy
Buy
Analyst Count
7
19
Target Price
★ $111.57
$12.66
AVG Volume (30 Days)
869.4K
★ 19.5M
Earning Date
10-27-2026
10-29-2026
Dividend Yield
N/A
★ 9.91%
EPS Growth
★ 225.00
N/A
EPS
★ 1.14
0.07
Revenue
★ $677,564,000.00
$567,754,000.00
Revenue This Year
$54.80
$0.65
Revenue Next Year
$28.50
$9.48
P/E Ratio
★ $83.44
$132.57
Revenue Growth
★ 60.09
7.56
52 Week Low
$37.02
$7.95
52 Week High
$99.31
$17.00

Technical Indicators

Market Signals
Indicator
KNSA
OWL
Relative Strength Index (RSI) 58.64 41.27
Support Level $72.76 $9.14
Resistance Level $98.90 $9.50
Average True Range (ATR) 4.32 0.44
MACD -0.24 -0.10
Stochastic Oscillator 68.28 8.88

Price Performance

Historical Comparison
KNSA
OWL

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

About OWL Blue Owl Capital Inc.

Blue Owl Capital is one of the world's largest alternative-asset managers, $307.4 billion in total managed assets, including $187.7 billion in fee-earning AUM, at the end of 2025. The company has three core business segments: global private equity, (with $69.1 billion in total AUM and $39.5 billion in fee-earning AUM), private credit ($157.7 billion/$99.5 billion), and real estate/real assets ($80.6 billion/$48.7 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). Blue Owl operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.

Share on Social Networks: